Hims & Hers Health (NYSE:HIMS) Trading 4.9% Higher - Still a Buy?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price was up 4.9% during mid-day trading on Thursday . The stock traded as high as $43.19 and last traded at $43.44. Approximately 16,078,287 shares were traded during trading, a decline of 29% from the average daily volume of 22,633,390 shares. The stock had previously closed at $41.41.

Analysts Set New Price Targets

HIMS has been the subject of a number of recent research reports. Truist Financial set a $45.00 price target on shares of Hims & Hers Health in a report on Tuesday. UBS Group set a $30.00 price target on Hims & Hers Health in a report on Monday. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a report on Monday. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and an average target price of $38.31.

Hims & Hers Health Price Performance

The company has a fifty day moving average price of $49.27 and a 200 day moving average price of $39.37. The company has a market capitalization of $10.20 billion, a P/E ratio of 66.76, a price-to-earnings-growth ratio of 1.62 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm's revenue was up 110.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.05 EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 17,102 shares of the stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the transaction, the insider now owns 278,654 shares in the company, valued at $16,649,576.50. This represents a 5.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $60.22, for a total transaction of $697,407.82. Following the transaction, the chief financial officer now directly owns 113,816 shares in the company, valued at approximately $6,853,999.52. The trade was a 9.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 706,454 shares of company stock valued at $35,220,112 in the last ninety days. Company insiders own 13.71% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HIMS. Farallon Capital Management LLC boosted its stake in Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. grew its position in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Nuveen LLC bought a new stake in shares of Hims & Hers Health during the 1st quarter worth $58,403,000. Finally, Renaissance Technologies LLC raised its position in shares of Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.